Business Investment Opportunities

Located in Tamluk, this upcoming polyclinic aims to offer comprehensive diagnostic and super-specialty doctor consultations under one roof. - The center will also offer endoscopy, colonoscopy, ERCP, and other advanced diagnostic procedures. - Designed to provide daily consultations from super-specialty doctors across multiple fields to address a wide range of health issues. - Owned by healthcare professionals with 15+ years of experience in hospital marketing and operations. - Registered with the Ministry of Corporate Affairs (MCA), ensuring full compliance and business credibility. - Expected to start operations within two months, with plans to serve as a key healthcare hub in Tamluk. - Positioned to address the growing demand for quality healthcare services in the region.

Our company offers a proprietary online healthcare portal that allows its users to book a broad range of healthcare services. - The portal is essentially a website and we do not have any mobile application as of now. However, they are under development and will be launched in the upcoming months. - Currently, our partnered hospitals, diagnostic centres, ambulances, donors and all our services are based only in 4 districts of Bangladesh: Khulna, Barishal, Jashore, and Satkhira. - We are partnered with 80 hospitals who have enlisted their 400 doctors on our portal. Users can simply visit our website, choose their desired doctors and book an appointment with them directly. - Our portal also has over 100 partnered diagnostic centres who have enlisted their radiology services on our platform. Users can simply choose and book their desired radiology test and then visit diagnostic centre. - We have over 3,000 active blood donors registered on our portal. Anyone who wishes to become a donor, can visit our website and register as a donor. Any user who is looking for blood for either themselves or their relatives can connect with blood donors through our platform. - The portal has partnered with over 20 ambulance service providers. Users who is in immediate need of an ambulance can connect with the service providers through our platform. - We facilitate about 900 successful doctor's appointments and 250 diagnostics appointments every month through our platform. The number of successful connections with blood donors and booked ambulance services varies each month. - Currently, the company is generating the entire revenue through our doctor's appointments services. Our diagnostic appointment booking services will begin monetising in the upcoming months. However, we do not plan on monetising our blood-donor connection and ambulance-booking services in the future. - The company generates revenue by charging the partnered hospital. The user does not have to pay any amount for booking the services. The hospital pays us a monthly fee that is either BDT 1,500 or BDT 3,000 for getting appointment leads through our website. The fee remains fixed regardless of the number of leads we send. The fee varies as per the number of doctors the hospital is enlisting on the portal. - We have 35 fee-paying hospitals for now and the remaining hospitals are not paying any fee yet. Currently, this is the only source of revenue for the company. - However, in the upcoming months, we will begin charging the remaining partnered hospitals. The same revenue model will be followed with our partnered diagnostic centres as they are not paying any fee right now. - The business is extremely valuable due to the large number of partnerships we have established over time along with our niche business activities in the Bangladeshi market.

To date, the company has 140 clients. The business model is based on four key elements: - Clients – The model operates as a public company with partners as beauty consultants. The source of business consultants is primarily the community, consisting of over 6,000 beauticians, with each consultant managing an average portfolio of 700 end clients. Additionally, there are 35,000 beauty centres in Italy, providing a potential customer market of 24.7 million people. - Products and devices – Cosmeceuticals and nutraceuticals are co-created with partners/beauty consultants, characterized by a formulation patent and supported by the University of Camerino (Italy). The devices include a 3D body scan and a virtual reality system for mental wellness, based on three patents incorporating vision and artificial intelligence techniques. - Channels – The business is conducted through beauty consultants, the AI Platform, IoT, Big Data, a B2B e-commerce platform, and dedicated mentoring. - Profits – Revenue is generated from three lines: diagnostic and treatment products and devices, user licenses for the software platform, and training and consulting services. Direct customer management, without intermediary sales networks, combined with tools like mentoring and the software platform to enhance efficiency and performance, results in margins twice as high as the average, with EBITDA close to 30%. The company benefits from a vast network of relationships developed by the founders over 30 years in the sector, along with undisputed leadership in advanced training for aesthetics and wellness. - The co-founder, R&D, and chairman of the board of directors, is a beauty practitioner, pharmacist, cosmetologist chemist, trainer, and creator of the beautician's community. He was also the former founder of a popular brand, managing 600 clients and over 60 employees in his last company, which generated €6M in revenue. Additionally, he has developed and managed distribution in several foreign markets, including Canada, the UK, Russia, France, Belgium, Spain, Poland, Germany, Portugal, and Switzerland.

Located in Kolkata, this multi-specialty hospital features a capacity of 125 beds, offering a range of medical services to the local community. - The hospital is fully equipped with outpatient and inpatient facilities, including an operating theatre (OT), intensive care unit (ICU), pharmacy, imaging, diagnostic lab, dialysis unit, and general wards. - The latest annual sales were reported at ₹8.55 crore. Sales have seen a slight decline this year compared to the previous year, primarily due to operational burn and reinvestment of revenue back into the business for growth and expansion. - The current EBITDA margin of -7.68% indicates the hospital is in a growth phase, focusing on long-term benefits over short-term profits. - The hospital is fully compliant with local regulations, holding an MCA registration, trade license and a pharmacy registration, ensuring a legitimate and trustworthy operation. - As an NABH-accredited facility, it meets the highest standards of healthcare in India, assuring potential investors of quality service and patient safety. - The hospital seeks investment for operational enhancement and service expansion, particularly in areas that improve patient care and medical technology.

The company is strategically positioned in the biotechnology sector, with plans to specialize in high-demand services such as flow cytometry and cell culture, tailored to support pharmaceutical, biotech, and diagnostic companies. - Despite being registered 4 years ago, the company has yet to start operations but has laid the groundwork through strategic collaborations and grant submissions totalling approximately USD 40 million, showcasing a strong potential for funding acquisition. - The promoter's extensive background, with a PhD in cell biology and two decades of research experience, provides a strong foundation for the company's technical expertise and leadership. - Possession of distribution rights for crucial research kits and therapeutic proteins indicates early-stage readiness to supply essential products to the research community. - The company maintains strategic collaborations with antibody-based firms, enhancing its capability to provide comprehensive solutions for advanced therapeutic and research needs. - Haverhill, the company's location, provides access to a strategic geographical position that can facilitate partnerships with key biotech and pharmaceutical players. - The planned service offerings, including advanced flow cytometry and specialized cell culture services, underscore the company's commitment to supporting cutting-edge research with reliable and customizable solutions.